Table 4—

HR for end points included in total cardiovascular events and procedures (diabetic patients only)

Atorvastatin
Placebo
Unadjusted HR (95% CI)P value
n (%)Raten (%)Rate
Fatal CHD17 (1.4)4.210 (0.8)2.41.72 (0.79–3.76)0.167
Fatal stroke5 (0.4)1.210 (0.8)2.40.51 (0.17–1.48)0.207
Other fatal cardiovascular4 (0.3)11 (0.1)0.24.07 (0.45–36.41)0.174
Nonfatal myocardial infarction22 (1.7)5.536 (2.8)8.90.62 (0.37–1.06)0.077
Unstable angina9 (0.7)2.312 (0.9)2.90.76 (0.32–1.81)0.541
Chronic stable angina9 (0.7)2.319 (1.5)4.70.48 (0.22–1.06)0.063
Life-threatening arrhythmias3 (0.2)0.71 (0.1)0.23.07 (0.32–29.51)0.306
Nonfatal heart failure15 (1.2)3.813 (1.0)3.21.18 (0.56–2.49)0.656
Nonfatal stroke23 (1.8)5.831 (2.4)7.70.76 (0.44–1.30)0.308
Peripheral arterial disease10 (0.8)2.512 (0.9)30.85 (0.37–1.97)0.706
Retinal vascular thromboses1 (0.1)0.21 (0.1)0.21.03 (0.06–16.54)0.981
Coronary revascularization procedures13 (1.0)3.326 (2.0)6.40.51 (0.26–0.99)0.044
Other revascularization procedures2 (0.2)0.59 (0.7)2.20.23 (0.05–1.06)0.060
Transient ischemic attack5 (0.4)1.313 (1.0)3.20.39 (0.14–1.10)0.064
Reverse ischemic neurodeficit3 (0.2)0.77 (0.5)1.70.44 (0.11–1.69)0.216